Expanded Access Programs offer a variety of benefits to the sponsoring pharmaceutical company.
These regulatory approved programs provide companies with additional opportunities to assess a drug prior to the full launch
Companies can generate additional safety and real world data that helps in understanding how the drug will be used in clinical practice
Sponsors can manage risk in the pre-launch setting through appropriate adverse event capture and screening patients to ensure the correct cohorts are selected to take the medicine
The programs give physicians experience with using the new medicine, creating advocates for the drug prior to its launch
EAPs help a company build relationships with both doctors and patients
If you are a Sponsor and have a product that is in development and you require the deployment of a EAP or distribution of your drugs to manage product requests from patients/physicians, please contact us.